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We compared the results of randomised trials comparing taxane-containing chemotherapy regimens with regimens not containing a
taxane in women with metastatic breast cancer. The specialised register of the Cochrane Breast Cancer Group was searched in
March 2004. Eligibility was assessed and data extracted from eligible studies by two reviewers. Hazard ratios (HR) were derived for
time-to-event outcomes, and a fixed-effect model was used for meta-analysis. Tumour response rates were analysed as dichotomous
variables. Of 21 eligible trials, 16 had published some results and 12 data on overall survival. An estimated 2621 deaths among 3643
women suggest a significant difference in overall survival in favour of taxane-containing regimens (HR 0.93, 95% confidence interval
(CI) 0.86–1.00, P¼0.05). The treatment effect on survival was similar if only trials of first-line chemotherapy were included, although
not statistically significant. There appeared to be an advantage for taxanes in time to progression (HR 0.92, 95% CI 0.85–0.99,
P¼0.02) and overall response (odds ratio (OR) 1.34, 95% CI 1.18–1.52, Po0.001). There was significant heterogeneity across the
trials (Po0.001), partly because of the varying efficacy of the comparator regimens. Taxane-containing regimens improved overall
survival in women with metastatic breast cancer. Taxane-containing regimens are more effective than some, but not all, nontaxane-
containing regimens.
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Taxanes are among the most active chemotherapy agents used
in the management of metastatic breast cancer. Paclitaxel was
identified in 1971 as part of a National Cancer Institute (NCI)
programme that screened medicinal plants for potential anticancer
activity, and was first used in clinical trials in 1983 (Breast cancer:
taxane clinical perspectives, 1996). Docetaxel was synthesised in
1986 and is similar to paclitaxel in its mechanism of action.
Initially, the use of taxanes was limited by hypersensitivity
reactions, but once these were better managed (largely by
premedication with steroids), taxane use became more frequent.
Taxanes have become part of standard management in most
western countries and are used as single agents or in combination
with other chemotherapeutic drugs or the monoclonal antibody
trastuzumab (Bernard-Marty et al, 2003).
The effect of taxanes on survival compared with other drugs
or drug combinations is unclear. We therefore conducted a
systematic review and meta-analysis to identify and synthesise
the results of randomised clinical trials comparing taxane-
containing chemotherapy regimens with regimens that did
not contain a taxane. Prospectively, we asked the following
questions:
(Q1) Regimen A plus taxane vs Regimen A (e.g. doxorubicin plus
docetaxel vs doxorubicin alone)
(Q2) Regimen A plus taxane vs Regimen B (e.g. doxorubicin plus
docetaxel vs doxorubicin plus cyclophosphamide)
(Q3) Single agent taxane vs Regimen C (e.g. docetaxel vs doxo-
rubicin plus cyclophosphamide).
The planned outcome measures were survival (date randomised
to date of death), time to progression (date randomised to date of
progression or death), time to treatment failure, overall response,
toxicity (specifically leukopenia, neurotoxicity, nausea or vomiting
and treatment-related death) and quality of life.
MATERIALS AND METHODS
Properly randomised controlled trials (i.e. where sequence
generation and allocation concealment were adequate) comparing
any regimen containing a taxane with any regimen not containing
a taxane as first-line treatment for metastatic breast cancer were
eligible. Trials that included both women with metastatic disease
and women with isolated locoregional recurrent disease were
eligible for inclusion if it was possible to distinguish between the
two groups (data were reported separately) or if women with
isolated locoregional recurrence were o20% of the total group.
There were no age restrictions. Trials in which the primary
intention was to investigate sequencing of treatment regimens
were excluded.
The primary outcomes were survival and time to progression for
which the hazard ratio (HR) is the most appropriate statistic.
When possible, the HR and associated variances were extracted
directly from the trial publication/s. If not reported, it was
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sobtained indirectly using the methods described by Parmar et al
(1998) using either other available summary statistics or from
data extracted from published Kaplan–Meier curves. To allow for
immature follow-up, the numbers at risk were adjusted based on
estimated minimum and maximum follow-up times
A pooled HR was obtained from the derived observed (O)–
expected (E) number of events and the variance for each trial
using the fixed effect model (Yusuf et al, 1985). The pooled HR
represents the overall risk of an event on taxane-containing
chemotherapy vs nontaxane-containing chemotherapy. w
2 tests for
heterogeneity were used to test for heterogeneity over all trials (see
Alderson et al, 2003). Post hoc subgroup analyses were conducted
for the type of taxane and prior exposure to anthracyclines. w
2 tests
for interaction were applied to these subgroup analyses.
RESULTS
On 12 March 2004, the search strategy in Table 1 was applied to the
specialised register of trials maintained by the Cochrane Breast
Cancer Group (see Search Strategy), resulting in the identification of
195 references to potentially eligible trials from the 7164 references
on the register. We identified 21 eligible studies, of which three are
ongoing (Table 2) (Dieras et al, 1995; Bishop et al, 1999; Chan et al,
1999; Nabholtz et al, 1999, 2003; Sjostrom et al, 1999; Luck et al,
2000; Paridaens et al, 2000; Bonneterre et al, 2001, 2002, 2003;
Jassem et al, 2001; Zielinski et al, 2001; Biganzoli et al, 2002; Icli
et al,2 0 0 2 ;T a l b o tet al, 2002; Bontenbal et al, 2003; Sledge et al,
2003; Goldhirsch, 2005; Heidemann, 2005). An additional two
studies were identified but excluded: the status of one as a
randomised trial was unclear (Gebbia et al, 2003), and the second
randomised women to cease vs continue paclitaxel (Gennari et al,
2001). Not all trials reported on all outcomes. Some were less mature
studies than others and had been reported in abstract form only.
Although the intention was to include only trials of first-line
chemotherapy (i.e. no chemotherapy had been given except as
adjuvant therapy), over half of the completed and published trials are
of more-than-first-line therapy. All trials meeting the remaining
eligibility criteria were therefore included in the review, and separate
analyses were conducted for line of therapy. All trials eligible for
Question 1 (adding a taxane to a chemotherapy regimen) and
Question 2 (comparing any regimen containing a taxane with any
regimen not containing a taxane) are of first-line chemotherapy.
It was not possible to assess accurately the quality of
randomisation used in most studies owing to lack of information
in the published articles. If the imbalance between treatment arms
was deemed to be sufficient to lead to a suspicion of bias in the
randomisation process, then this is reflected in the quality grade
assigned to the randomisation process, details of which have been
reported elsewhere (Ghersi et al, 2005).
Over 6300 women had been randomised to the 21 eligible trials,
and time-to-event data for overall survival data were available for
57% of them. The data available for Question 3 (comparing a
single-agent taxane with any regimen not containing a taxane)
were more complete; nine of the 10 eligible trials (representing
2442 or 84% of the 2780 women randomised to this question) had
reported overall survival data.
One study was a three-armed trial eligible for both Questions 1
and 3 (Sledge et al, 2003). This was taken into account when the
overall effect of taxanes was calculated (by halving the control
group).
Overall survival
The trials of first-line chemotherapy suggest that there may be a
benefit in terms of overall survival in favour of taxanes, with an HR
of 0.92 (95% confidence interval (CI) 0.84–1.02, P¼0.11). When
all trials are included, there is a statistically significant difference
of similar magnitude in favour of taxane-containing regimens,
with an HR of 0.93 (95% CI 0.86–1.00, P¼0.05). There was no
statistically significant heterogeneity across the trials.
The results for those individual trials that reported on survival
are shown in Figure 1. Only three of the nine studies eligible for
Question 2 (comparing any regimen containing a taxane with any
regimen not containing a taxane) provided information on
survival, representing 35% of the estimated number of patients.
The three trials suggested that there might be a benefit in terms of
overall survival in favour of taxanes (HR 0.88, 95% CI 0.76–1.02,
P¼0.10), but this was not statistically significant.
Nine of the 10 studies eligible for Question 3 (comparing a
single-agent taxane with any regimen not containing a taxane)
reported on overall survival, which suggests a benefit in favour of
the taxane arm (HR 0.94, 95% CI 0.86–1.03, P¼0.19) with no
statistically significant heterogeneity. A similar but nonsignificant
effect was seen if trials with potentially suboptimal comparators
(those comparing taxane with mitomycin7vinblastine, and fluoro-
uracil with vinorelbine) (Dieras et al, 1995; Nabholtz et al, 1999;
Bonneterre et al, 2002) were excluded (HR 0.97, 95% CI 0.88–1.08,
P¼0.62), or if the analysis of this subgroup was limited to trials of
first-line chemotherapy (HR 0.95, 95% CI 0.83–1.10, P¼0.50).
Time to progression
Trials were not consistent in the way they defined this outcome.
Trials that started the clock at the time of randomisation were
included. Details of the definition used for this outcome for each
trial has been reported elsewhere (Ghersi et al, 2005).
The six trials of first-line chemotherapy suggest that there is no
detectable difference between taxane and nontaxane-containing
regimens (HR 0.99, 95% CI 0.90–1.09, P¼0.88). If data from all 11
of the 21 eligible trials reporting this outcome are included, there is
a statistically significant benefit in favour or taxanes (HR 0.92, 95%
CI 0.85–0.99, P¼0.02) (Figure 2). There was, however, significant
heterogeneity across trials for all time-to-progression analyses
(Po0.00001, I
2¼89.7%).
Only three of the 21 eligible trials reported data on time to
treatment failure. It was therefore not considered appropriate to
pool data across trials.
Overall response rates
Sufficient data from 15 of the 21 eligible trials were available to
enable an odds ratio (OR) for response rates to be calculated.
There were some differences in the definition of response across
(but not within) trials. The analysis of the 2787 assessable patients
in first-line trials indicate a statistically significant difference in
favour of taxane-containing regimens (OR 1.28, 95% CI 1.10–1.50,
P¼0.002). This difference remained when all trials reporting this
Table 1 Search strategy
The specialised register is based on a detailed search strategy consisting of
numerous MeSH headings and text word combinations. This strategy is applied
routinely to the Medline and Embase databases. Similar (although less detailed)
searches are conducted of the PDQ database and the Cochrane Central Register
of Controlled Trials. The major relevant conference proceedings are also searched
(either by hand or electronically) and included in the register. For further details,
please see the module of the Cochrane Breast Cancer Group published on the
Cochrane Library (Simes et al, 2005).
References on the register are coded to facilitate searching. The codes ‘advanced’
and ‘chemotherapy’ were applied to the specialised register and combined with
the Keywords (imported with the references from Medline) ‘Taxol’, ‘docetaxel’ or
‘paclitaxel’, and a search of all nonindexed fields for the following text words:
taxane, taxanes, taxol, taxotere, paclitaxel, paxene, nsc-125973, docetaxel or
anzatax.
The reference lists of publications of eligible studies and related literature reviews
were also searched.
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soutcome were included (OR 1.34, 95% CI 1.18–1.52, Po0.0001).
There was significant heterogeneity across trials for this outcome
(Po0.0001) (Figure 3).
Toxicity
Four of the nine studies eligible for Question 2 (comparing any
regimen containing a taxane with any regimen not containing a
taxane) reported on toxicity (Table 3). Taxanes were associated with
significantly more leukopenia and neurotoxicity, but less nausea
and vomiting in assessable patients. Of those eligible for Question 3
(comparing a single-agent taxane with any regimen not containing
a taxane), seven studies reported on leukopenia, nine on nausea or
vomiting and neurotoxicity and four on hair loss (Table 4). Taxanes
were associated with significantly worse neurotoxicity and hair loss,
but less leukopenia and nausea or vomiting.
Table 2 Studies included in the review
Trial ID Summary details
Arm 1: taxane
containing
a Arm 2: control
Majority
first line
for MBC
Majority
anthracycline
naı ¨ve Accrual
Regimen A plus taxane vs Regimen A
ECOG E1193 (A) (Sledge et al,
2003)
Open: 1993–1995 AT
(paclitaxel+doxorubicin+
G-CSF)
Doxorubicin Y Y 739
EU-93011 (Heidemann, 2005) Open: 1994–(ongoing) Docetaxel+mitoxantrone mitoxantrone Y Both 300
SAKK (Goldhirsch, 2005) Open: unk (ongoing) Paclitaxel+trastuzumab trastuzumab Y Both 170–250
Regimen A plus taxane vs Regimen B
306 Study Group (Nabholtz et al,
2003)
Open: 1996–1998 AT
(docetaxel+doxorubicin)
AC
(cyclophosphamide+
doxorubicin)
Y Y 429
Bontenbal (Bontenbal et al, 2003) Open: 1997–2002.
Abstract only
AT
(docetaxel+doxorubicin)
FAC
(fluorouracil+doxorubicin+
cyclophosphamide)
Y Y 216
Nabholtz (Nabholtz et al, 2001) Open: 1998–1999.
Abstract only
TAC
(docetaxel+doxorubicin+
cyclophosphamide)
FAC
(fluorouracil+doxorubicin+
cyclophosphamide)
Y N 484
EORTC 10961 (Biganzoli et al,
2002)
Open: 1996–1999 AT
(paclitaxel+doxorubicin)
AC
(cyclophosphamide+
doxorubicin)
Y Y 275
Jassem (Jassem et al, 2001) Open: 1996–1998 AT
(paclitaxel+doxorubicin)
FAC
(fluorouracil+doxorubicin+
cyclophosphamide)
Y Y 267
AGO (Luck et al, 2000) Open: 1996–1999.
Abstract only
ET
(paclitaxel+epirubicin)
EC
(cyclophosphamide+epirubicin)
YY 505
Bonneterre (Bonneterre et al,
2001)
Open: 1998–2000.
Abstract only
ET (docetaxel+epirubicin) FEC
(fluorouracil+epirubicin+
cyclophosphamide)
Y Both 141
UKCCCR AB01 (Carmichael,
2001)
Open: 1996–1999.
Abstract only.
ET
(paclitaxel+epirubicin)
EC
(cyclophosphamide+epirubicin)
Y Y 705
CECOG BM1 (Zielinski et al,
2001)
Open: 1999– (ongoing) GET
(paclitaxel, epirubicin,
gemcitabine)
FEC
(fluorouracil, epirubicin,
cyclophosphamide)
Y ? Sample size
unknown
Single agent taxane vs Regimen C
303 Study Group (Chan et al,
1999)
Open: 1994–1997 Docetaxel Doxorubicin N Y 326
304 Study Group (Nabholtz et al,
1999)
Open: 1994–1997 Docetaxel Mitomycin+vinblastine N N 392
Sjostrom (Sjostrom et al, 1999) Open: 1994–1997 Docetaxel MF
(methotrexate+fluorouracil)
N N 283
TXT Group (Bonneterre et al,
2002)
Open: 1995–1997 Docetaxel FUN
(fluorouracil+vinorelbine)
N N 176
ANZ TITG (Bishop et al, 1999) Open: 1993–1995 Paclitaxel CMFP
(cyclophosphamide+
methotrexate+fluorouracil+
prednisone)
Y Y 209
Dieras (Dieras et al, 1999) Open: unk Paclitaxel Mitomycin N N 81
ECOG E1193 (B) (Sledge et al,
2003)
Open:1993–199 Paclitaxel Doxorubicin Y Y 739
EORTC 10923 (Paridaens et al,
2000)
Open: 1993–1996 Paclitaxel Doxorubicin Y Y 331
Talbot (Talbot et al, 2002) Open: 1996–1997 Paclitaxel Capecitabine N N 42
TOG (Icli et al, 2002) Open: 1997–2002.
Abstract only
Paclitaxel Cisplatin+VP-16 N N 201
MBC¼metastatic breast cancer.
aAll taxane-containing regimens were 3-weekly cycles.
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In all, 10 trials had collected quality-of-life data, eight of which had
reported results (Bishop et al, 1999; Chan et al, 1999; Nabholtz
et al, 1999, 2003; Hakamies-Blomqvist et al, 2000; Kramer et al,
2000; Carmichael, 2001; Jassem et al, 2001; Biganzoli et al, 2002;
Sledge et al, 2003). The type of instrument used and the way in
which quality of life was reported varied across trials, as did the
completion rate by patients of quality-of-life instruments. Some
studies reported problems with patients in poorer health not
completing questionnaires (e.g. Nabholtz et al, 1999). For these
reasons, it was decided not to statistically pool quality-of-life data.
None of the individual trials reported a statistically signi-
ficant difference in overall quality of life, or in any of the sub-
scales, between taxane- and nontaxane-containing chemotherapy
regimens.
Treatment-related death
The trials reported 54 treatment-related deaths: 24 on taxane-
containing regimens and 30 on the nontaxane-containing regi-
mens. There was no statistically significant difference between the
two groups (OR 0.80, 95% CI 0.48–1.32, P¼0.41).
Study  Taxane containing  Control  Peto OR (IPD)  Peto OR (IPD)
or subcategory  n/N  n/N  95% CI  95% CI O − E Variance
01 Regimen A plus taxane vs Regimen A
 ECOG E1193 (A) (ATvA)      179/230             172/224       1.00 (0.82, 1.22) 
Subtotal (95% CI) 230                                       224      1.00 (0.82, 1.22)
Total events: 179 (taxane containing), 172 (control)
Test for heterogeneity: not applicable
Test for overall effect: Z = 0.02 (P = 0.98)
02 Regimen A plus taxane vs Regimen B
 Jassem (APvFAC)        80/134          95/133       0.68 (0.51, 0.92) 
EORTC 10961 (APvAC)       81/138          74/137       1.11 (0.83, 1.49) 
 306 SG (ATvAC)       165/214         176/215       0.89 (0.72, 1.09) 
Subtotal (95% CI) 486      0.88 (0.76, 1.02)
Total events: 326 (taxane containing), 345 (control)
Test for heterogeneity: ²  = 5.07, df = 2 (P = 0.08), I² = 60.5%
Test for overall effect: Z = 1.67 (P = 0.10)
03 Single agent taxane vs Regimen C
 Dieras (PvMitC)       20/36               16/36      1.59 (0.73, 3.46) 
TXT Group (TvFUN)       66/86               69/90      0.99 (0.72, 1.37) 
 TOG (PvCisp+VP16)        82/101              74/100       1.20 (0.88, 1.65) 
 ANZ TITG (PvCMFP)        75/107              82/102       0.75 (0.55, 1.02) 
 Sjostrom (TvMF)       102/143             105/139       0.99 (0.75, 1.29) 
 303 SG (TvA)       102/161             105/165       0.89 (0.68, 1.17) 
EORTC 10923 (PvA)      130/166             124/165       1.12 (0.87, 1.43) 
 304 SG (TvMit+Vbl)       137/203             138/189       0.73 (0.58, 0.93) 
 ECOG E1193 (B) (PvA)       172/229             172/224       0.95 (0.77, 1.16) 
Subtotal (95% CI)                1210      0.94 (0.86, 1.03)
Total events: 886 (taxane containing), 885 (control)
Test for heterogeneity: ² = 12.79, df = 8 (P  = 0.12), I² = 37.4%
Test for overall effect: Z = 1.31 (P = 0.19)
 0.5  0.7  1  1.5  2
 Favours taxane Favours control
485
1232
0.24
4.63
2.98
7.21
6.97
6.40
36.43
38.98
39.25
51.71
51.75
63.50
68.75
93.40
−16.10
−10.40
−0.27
−0.78
−6.19
−21.44
−4.88
−11.43
97.86
42.53
43.98
85.25
Figure 1 Overall survival. Overall HR for overall survival is 0.93, 95% CI 0.86–1.00, P¼0.05. Test for heterogeneity: w
2¼18.58, df¼12 (P¼0.10),
I
2¼35.4%.
Study  Taxane containing  Control  Peto OR (IPD)  Peto OR (IPD)
or subcategory  n/N n /N  95% CI  95% CI O - E Variance
01 Regimen A plus taxane vs Regimen A
 ECOG E1193 (A)(ATvA) 174/230  166/224       0.99 (0.81, 1.21) −0.70 94.92
47.63
64.94
76.37
17.25
43.34
50.50
66.50
70.58
78.50
79.00
91.09
−14.65
−3.78
−21.20
−8.93
−6.15
−38.38
−29.15
−4.83
34.58
25.58
8.17
Subtotal (95% CI) 230              224      0.99 (0.81, 1.21)
Total events: 174 (taxane containing), 166 (control)
Test for heterogeneity: not applicable
Test for overall effect: Z = 0.07 (P = 0.94)
02 Regimen A plus taxane vs Regimen B
 Jassem (APvFAC)  91/134 105/133       0.74 (0.55, 0.98) 
 EORTC 10961 (APvAC)  123/138 125/137       0.94 (0.74, 1.20) 
 306 SG (ATvAC) 151/214 165/215       0.76 (0.61, 0.95) 
Subtotal (95% CI) 486              485      0.81 (0.70, 0.94)
Total events: 365 (taxane containing), 395 (control) 
Test for heterogeneity: ² = 2.30 , df = 2 (P = 0.32), I² = 13.0%
Test for overall effect: Z = 2.88 (P = 0.004)
03 Single agent taxane vs Regimen C
 Dieras (PvMitC)  26/36  30/36       0.60 (0.37, 0.96) 
 TOG (PvCisp+VP16)  96/101  92/100       1.80 (1.34, 2.43) 
 ANZ TITG (PvCMFP)  103/107  99/102       1.18 (0.89, 1.55) 
 303 SG (TvA)  132/161 134/165       0.91 (0.72, 1.16) 
 Sjostrom (TvMF)  128/143 132/139       0.58 (0.46, 0.73) 
 304 SG (TvMit+Vbl)  161/203 153/189       0.69 (0.55, 0.86) 
 EORTC 10923 (PvA)  160/166 156/165       1.55 (1.24, 1.93) 
 ECOG E1193 (B) (PvA)  168/229 166/224       0.95 (0.77, 1.16) 
Subtotal (95% CI) 1146              1120      0.96 (0.88, 1.05)
Total events: 974 (taxane containing), 962 (control) 
Test for heterogeneity: ² = 67.96, df = 7 (P < 0.00001), I² = 89.7%
Test for overall effect: Z = 0.86 (P = 0.39)
 0.2  0.5  1  2  5
 Favours taxane  Favours control
Figure 2 Time to progression. Overall HR for time to progression is 0.92, 95% CI 0.85–0.99, P¼0.02. Test for heterogeneity: w
2¼74.41, df¼11
(Po0.00001), I
2-85.2%.
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sStudy  Taxane containing  Control  OR (fixed)  OR (fixed)
or subcategory  n/N  n/N  95% CI  95% CI
01 Regimen A plus taxane vs Regimen A
 ECOG E1193 (A)(ATvA)      108/230              81/224  1.56 (1.07, 2.28) 
Subtotal (95% CI) 230                 224 1.56 (1.07, 2.28)
Total events: 108 (taxane containing), 81 (control) 
Test for heterogeneity: not applicable
Test for overall effect: Z = 2.33 (P = 0.02)
02 Regimen A plus taxane vs Regimen B
 306 SG (ATvAC)       124/191             100/199  1.83 (1.22, 2.75) 
 Bontenbal (ATvFAC)        64/99               40/97       2.61 (1.46, 4.64) 
 EORTC 10961 (APvAC)        80/125              74/128       1.30 (0.78, 2.15) 
 Jassem (APvFAC)        87/128              73/131       1.69 (1.02, 2.80) 
 Nabholtz (TACvFAC)       129/238             102/237       1.57 (1.09, 2.25) 
Subtotal (95% CI) 781                 792      1.70 (1.39, 2.08)
Total events: 484 (taxane containing), 389 (control)
Test for heterogeneity: ² = 3.53, df = 4 (P = 0.47), I² = 0%
Test for overall effect: Z = 5.17 (P < 0.00001)
03 Single agent taxane vs Regimen C
 303 SG (TvA)        77/148              55/147       1.81 (1.14, 2.89) 
 ECOG E1193 (B)(PvA)        78/229              81/224       0.91 (0.62, 1.34) 
 EORTC 10923 (PvA)        42/164              67/163       0.49 (0.31, 0.79) 
 Dieras (PvMitC)         6/36                7/36       0.83 (0.25, 2.76) 
 Sjostrom (TvMF)       61/130              29/127       2.99 (1.74, 5.12) 
 TXT Group (TvFUN)        37/86               35/90       1.19 (0.65, 2.17) 
 Talbot (PvCape)         5/19       8/22       0.63 (0.16, 2.39) 
 TOG (PvCisp+VP16)        21/94               33/91       0.51 (0.26, 0.97) 
 304 SG (TvMit+Vbl)        87/128              72/131       1.74 (1.05, 2.88) 
 ANZ TITG (PvCMFP)        31/105              36/99       0.73 (0.41, 1.32) 
Subtotal (95% CI) 1139                1130      1.08 (0.91, 1.28)
Total events: 445(taxane containing), 423 (control) 
Test for heterogeneity: ² = 41.23, df = 9 (P < 0.00001),I² = 78.2%
Test for overall effect: Z = 0.87 (P = 0.38)
 0.2  0.5  1  2  5
 Favours control  Favours taxane
Figure 3 Overall response. Overall OR for overall response is 1.34, 95% CI 1.18–1.52, Po0.0001. Test for heterogeneity: w
2¼55.41, df¼15
(Po0.00001), I
2¼72.9%.
Table 3 Acute toxicity, grades III and IV combined: Regimen A+taxane vs Regimen B
Site of toxicity Number of trials Taxane events/patients Control events/patients OR (95% CI)
Assessable patients
Leukopenia
a 4 (a, b, c, d) 538/591 470/585 2.48 (1.75–3.52)
Nausea or vomiting
b 3 (a, b, c) 32/472 59/471 0.51 (0.32–0.80)
Neurotoxicity 3 (a, b, c) 20/466 0/469 43.11 (2.60–714.94)
Randomised patients
Leukopenia
a 4 (a, b, c, d) 538/595 470/591 2.43 (1.73–3.41)
Nausea or vomiting
b 3 (a, b, c) 32/487 59/484 0.51 (0.32–0.79)
Neurotoxicity 3 (a, b, c) 20/487 0/484 42.49 (2.56–704.56)
OR¼odds ratio; CI¼confidence interval. a¼EORTC 10961; b¼Jassem; c¼306 Study Group, d¼Bontenbal. Note: Jassem reported 264 of the 267 patients received
treatment but did not report denominator for each treatment arm. Assumed % of randomised patients.
aData on grade III or IV neutropenia was included if data on leukopenia
was not reported.
bIf data on nausea and vomiting were reported separately, data on vomiting was included.
Table 4 Acute toxicity, grades III and IV combined: single-agent taxane vs Regimen C
Site of toxicity Number of trials Taxane events/patients Control events/patients OR (95% CI)
Assessable patients
Leukopenia 7 (a, b, c, d, g, h, i) 334/655 422/663 0.59 (0.48–0.74)
Nausea or vomiting 9 (a, b, c, d, e, f, g, h, i) 30/1007 92/1000 0.30 (0.20–0.46)
Neurotoxicity 9 (a, b, c, d, e, f, g, h, i) 63/1007 10/1000 6.61 (3.37–12.95)
Hair loss 4 (a, h, i) 119/210 31/211 7.59 (4.75–12.13)
Randomised patients
Leukopenia 7 (a, b, c, d, g, h, i) 334/682 422/684 0.60 (0.48–0.74)
Nausea or vomiting 9 (a, b, c, d, e, f, g, h, i) 30/1028 92/1012 0.30 (0.20–0.46)
Neurotoxicity 9 (a, b, c, d, e, f, g, h, i) 63/1028 10/1012 6.54 (3.34–12.82)
Hair loss 4 (a, h, i) 119/213 31/214 7.47 (4.68–11.92)
OR¼odds ratio; CI¼confidence interval. a¼ANZ TITG; b¼Chan; c¼Dieras; d¼EORTC 10923; e¼Nabholtz 1; f¼Sjostrom; g¼TOG; h¼TXT Study Group; i¼Talbot.
Note: ANZ TITG and TXT Study Group both graded hair loss using the WHO criteria, and Talbot used the NCIC Common Toxicity Criteria.
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Single-agent taxane compared with single-agent anthracycline
The three trials comparing single-agent taxane with single-agent
anthracycline (an estimated 916 events in 1110 women) showed no
detectable difference in time to progression (HR 1.10, 95% CI
0.97–1.26, P¼0.12) with some evidence of heterogeneity
(P¼0.001). An estimated 812 deaths in 1110 women showed no
detectable difference in overall survival (HR 1.00, 95% CI 0.88–
1.15, P¼0.94) and no statistically significant heterogeneity.
Single-agent taxane compared with nonanthracycline-containing
combinations The six trials comparing single-agent taxane
with a nonanthracycline-containing combination (estimated 966
deaths in 1332 women) favoured taxane-containing regimens for
overall survival (HR 0.91, 95% CI 0.80–1.03, P¼0.13) with no
statistically significant heterogeneity. For time to progression, the
five studies with usable data (1020 events in 1156 women) favoured
taxane-containing regimens (HR 0.85, 95% CI 0.75–0.96,
Po0.0008), with statistically significant heterogeneity (Po0.0001,
I
2 91.3%).
Type of taxane Post hoc subgroup analyses were conducted to
investigate the treatment effect within the types of taxane. Data
from the 2038 women randomised to seven trials using paclitaxel
show no detectable difference in overall survival (HR 0.97, 95% CI
0.87–1.07, P¼0.54) or in time to progression. Data from the 1605
women randomised to five trials using docetaxel showed a
statistically significant difference in overall survival and time to
progression in favour of the taxane-containing regimen (HR for
overall survival 0.88, 95% CI 0.78–0.98, P¼0.02) with no
statistically significant heterogeneity.
There was a statistically significant difference in time to
progression between women who had received docetaxel com-
pared to those who had received paclitaxel (test for interaction
Po0.001) (Figure 4). The interpretation of this result is
complicated by the significant heterogeneity in both the docetaxel
and paclitaxel trials and may relate to the choice of comparator in
these trials.
Previous exposure to anthracyclines Post hoc subgroup analyses
were also used to investigate the treatment effect in patients who
had or had not received previous anthracyclines. Data from the
1123 women randomised to the five trials in women who had
received anthracyclines favoured taxane-containing regimens in
terms of overall survival (HR 0.94, 95% CI 0.82–1.08, P¼0.39) and
time to progression. There was no detectable difference for either
outcome in anthracycline-naive women, although there was a
significant difference in favour of taxanes for overall response
(OR 1.21, 95% CI 1.03–1.43, P¼0.02). There was statistically
significant difference in time to progression (P¼0.006) between
women who had received prior anthracyclines and those who had
not (Po0.001) (Figure 5).
DISCUSSION
Despite the relative immaturity of many of the studies included
in this review, there is sufficient evidence to conclude that on
average, taxane-containing regimens are associated with a
statistically significant improvement in overall survival compared
with nontaxane-containing regimens. This is consistent with
emerging data from trials employing taxanes in the adjuvant
setting (Nowak et al, 2004).
Conclusions about the effects of taxanes on other end points
(such as response rate and time to progression), the effects of
taxanes in various subgroups and the differential effects of
paclitaxel and docetaxel are of clinical interest, but are statistically
less secure. Taxane-containing regimens were associated with
more leukopenia and neurotoxicity, but less nausea and vomiting,
than the control group, and the effect on quality of life did not
appear to differ in any of the trials.
At the time of this review, overall survival data were available for
only 12 of the 20 eligible trials. This may relate to the relative
immaturity of some of the trials, or reporting bias (specifically the
tendency to report positive results early) may exist. There may also
be unpublished trials that were not identified in our search. The
treatment effects reported may therefore be overestimated.
The initial eligibility criteria for this review limited trials to
those comparing taxane- with nontaxane-containing regimens
as first-line chemotherapy. A decision was made to include
comparisons of more-than-first-line chemotherapy owing to the
limited number of completed trials (most of the first-line trials had
not reported survival data). Results for overall survival and time to
Study
or subcategory
Taxane containing
n/N
Control
n/N
Peto OR (IPD)
95% Cl 
Peto OR (IPD)
95% Cl 
Weight
%
1 1.5 2.0 0.7
Favours taxane Favours control
0.5
01 Paclitaxel containing
ANZ TITG
ECOG E1193 (A)
ECOG E1193 (B)
ECRTC 10923
ECRTC 10961
Dieras
Jassem
TOG
CECOG BM1
Subtotal (95% Cl)
Total events: 941 (taxane containing), 773 (control)
Test for heterogeneity: 
2 = 40.10, df = 8 (P < 0.00001), I
2 = 80.1%
Test for overall effect: Z = 1.36 (P = 0.17)
02 Docetaxel containing
303 Study Group
304 Study Group
Sjostrom
306 Study Group
Subtotal (95% CI)
Total events: 572 (taxane containing), 584 (control)
Test for heterogeneity: 
2 = 7.31, df = 3 (P = 0.06), I
2 = 59.0%
Test for overall effect: Z = 5.55 (P < 0.00001)
103/107
174/230
168/229
160/166
26/36
123/138
91/134
96/101
0/1
1142
132/161
132/161
128/143
151/214
721
99/102 10.76 1.18 (0.89, 1.55)
0.97 (0.76, 1.25)
0.92 (0.72, 1.19)
1.55 (1.24, 1.93)
0.60 (0.37, 0.96)
0.94 (0.74, 1.20)
0.74 (0.55, 0.98)
1.80 (1.34, 2.43)
0.89 (0.66, 1.20)
1.06 (0.97, 1.17)
0.91 (0.72, 1.16)
0.69 (0.55, 0.86)
0.58 (0.46, 0.73)
0.76 (0.61, 0.95)
0.72 (0.64, 0.81)
13.38
12.95
16.83
3.68
13.84
10.15
9.23
9.18
100.00
22.78
26.89
24.18
26.16
100.00
83/112
83/112
156/165
30/36
125/137
105/133
92/100
134/165
153/189
132/139
165/215
708
0/1
898
Figure 4 Time to progression for subgroup type of taxane.
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suggest a benefit in favour of taxane-containing regimens, but this
is not statistically significant. Nevertheless, the observed results are
consistent with those based on all trials and may be due to lack of
statistical power.
Some heterogeneity across the trials is to be expected given the
different drugs, dosages and schedules being used and the different
patient groups and treatment settings. There is, however, strong
statistical evidence of heterogeneity among the trials in the effect
of treatment on time to progression and response (Po0.00001),
and one explanation for this is the varying efficacy of the
comparator regimens. For example, the regimens of mito-
mycin7vinblastine, and fluorouracilþvinorelbine could be re-
garded as suboptimal chemotherapy for breast cancer. If these
regimens are excluded, the advantages for a single-agent taxane,
when compared with a nontaxane-containing regimen, are no
longer statistically significant. While opinions will vary regarding
those regimens that could be considered to be suboptimal, it is
reasonable to conclude that taxanes are more effective than some,
but not all, regimens with which they have been compared, and
are at least as effective as the other regimens.
The analyses of most relevance to clinical practice are
comparisons of the different taxanes, and the contexts in which
they are used (i.e. in anthracycline-naı ¨ve patients or not). The
available data suggest that docetaxel may be more active than
paclitaxel, at least when given in 3-weekly schedules. This is based
on an indirect comparison of these two drugs in trials with
statistical heterogeneity, but is consistent with the preliminary
results of a trial directly comparing the taxanes (Jones et al, 2003).
Furthermore, weekly schedules of taxanes are now commonly
used and may have a different efficacy-to-toxicity ratio. Ongoing
trials, in all stages of breast cancer, are investigating the relative
efficacy of different taxanes and different schedules of those
taxanes. The benefit of taxanes also appears to be less apparent
in patients who have not had previous anthracyclines. While
subset analyses may be useful for informing clinical practice,
interpreting such analyses requires caution, given the smaller
number of patients in each subgroup, and the potential effect of
confounding.
This review includes data from 12 studies (3643 randomised
women) reporting time-to-event outcomes, and 16 studies (4287
randomised women) reporting response as an outcome. When
complete, the data from all 21 eligible studies will contribute
information on over 6000 randomised women to future updates of
this review.
This paper is based on a Cochrane review published in the
Cochrane Library 2004, Issue 3 (see www.CochraneLibrary.net for
information). Cochrane reviews are regularly updated as new
evidence emerges and in response to comments and criticisms, and
the Cochrane Library should be consulted for the current version
of the review.
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